Clinical Trial Update: Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders [Phase 2, Phase 3]

View source ↗

Summary

Amgen’s long-term trial of a PCSK9 inhibitor in subjects with familial hypercholesterolemia has completed Phase 2/Phase 3 and results have been posted. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Sponsor: Amgen | Conditions: Severe Familial Hypercholesterolemia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-01-28